In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

A look at the financing, M&A and alliance activity July–September 2017

Executive Summary

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Advertisement

Related Content

US FDA Implements 'Firm-Based' Regulatory Approach To DTC Genetic Health Risk Tests
Teva Offloads Women's Health Business To Two Firms For $1.38Bn
Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm
Teleflex Adds Minimally Invasive BPH System With NeoTract Buy
Fresenius Homes In On NxStage
Invitae Scores M&A Double Whammy In Reproductive Health Dx
Alere Off-Loads Blood Gas Business To Siemens
Alere Unloads Its Triage Assets To Quidel
Konica Minolta Adds Ambry Genetics As First Piece Of Precision Medicine Business
Despite Legal Dispute, Abbott Set To Buy Alere for $5.3bn

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV005232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel